DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 20-522/S-021, S-022

Genentech, Inc.
Attention: Pat Harada
Regulatory Affairs
1 DNA Way
South San Francisco, CA 94080-4990

Dear Ms. Harada:

Please refer to the following supplemental new drug applications submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Nutropin AQ [somatropin (rDNA origin) injection]:

Supplement -021, submitted January 30, 2004, provides for the addition of long-term treatment of idiopathic short stature as an indication.

Supplement -022, submitted March 11, 2004, provides for revisions to the CONTRAINDICATIONS and WARNINGS sections of the package insert regarding the treatment of Prader Willi Patients.

We acknowledge receipt of your submissions dated February 3, March 17, September 10, October 4 and 13, and November 1, 2004, to supplement -021, and submissions dated September 7, October 5, and November 1, 2004, to Supplement -022.

Your submission of October 5, 2004, constituted a complete response to our September 10, 2004, action letter for supplement -022.

We completed our review of these applications, as amended. These applications are approved, effective on the date of this letter, for use as recommended in the attached agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert).

Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA*. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission "**FPL for approved supplement NDA 20-522/S-021, S-022**." Approval of this submission by FDA is not required before the labeling is used.

All applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred. We note that you have fulfilled the pediatric study requirement for this application.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HFD-410
FDA
5600 Fishers Lane
Rockville, MD 20857

We encourage the continuation of your ongoing North American postmarketing surveillance study entitled, National Cooperative Growth Study (NCGS) in which patients are enrolled regardless of the indication for growth hormone treatment. Patients are followed throughout their course of treatment by means of periodic office visits. The program collects reported adverse events regardless of assessed relationship to growth hormone.

We also remind you of the risk management plan related to the use of Nutropin AQ for idiopathic short stature that you plan to implement as outlined in your submissions dated December 18, 2003 and October 13, 2004. Elements of that plan include:

- Healthcare professional education
- Limited marketing to physicians and nurses specializing in endocrinology and nephrology
- Limited and specially trained sales force
- No direct-to-consumer advertising
- Controlled distribution process

We request that you provide FDA with information about any changes to this plan at the time the changes are made and periodically report to FDA data on the extent of use of Nutropin AQ for idiopathic short stature.

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Kati Johnson, Chief, Project Management Staff, at (301) 827-6380.

Sincerely,

{See appended electronic signature page}

David G. Orloff, MD
Director
Division of Metabolic and Endocrine Drug Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

Enclosure: draft package insert

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

David Orloff

6/28/05 04:40:53 PM